 Receptors, Androgen
"Receptors, Androgen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA.
| Descriptor ID |
D011944
|
| MeSH Number(s) |
D12.776.260.698.750.150 D12.776.826.750.150 D12.776.930.669.750.150
|
| Concept/Terms |
Receptors, Androgen- Receptors, Androgen
- Androgen Receptor
- Receptor, Androgen
- Androgen Receptors
- Dihydrotestosterone Receptors
- Testosterone Receptor
- Receptors, Androgens
- Androgens Receptors
- Receptors, Dihydrotestosterone
- Receptors, Stanolone
- Stanolone Receptors
- Stanolone Receptor
- Receptor, Stanolone
- 5 alpha-Dihydrotestosterone Receptor
- 5 alpha Dihydrotestosterone Receptor
- Receptor, 5 alpha-Dihydrotestosterone
- alpha-Dihydrotestosterone Receptor, 5
- Receptor, Testosterone
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Androgen".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- DNA-Binding Proteins [D12.776.260]
- Receptors, Cytoplasmic and Nuclear [D12.776.260.698]
- Receptors, Steroid [D12.776.260.698.750]
- Receptors, Androgen [D12.776.260.698.750.150]
- Receptors, Cytoplasmic and Nuclear [D12.776.826]
- Receptors, Steroid [D12.776.826.750]
- Receptors, Androgen [D12.776.826.750.150]
- Transcription Factors [D12.776.930]
- Receptors, Cytoplasmic and Nuclear [D12.776.930.669]
- Receptors, Steroid [D12.776.930.669.750]
- Receptors, Androgen [D12.776.930.669.750.150]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Androgen".
This graph shows the total number of publications written about "Receptors, Androgen" by people in UAMS Profiles by year, and whether "Receptors, Androgen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 1 | 1 | 2 | | 2021 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2015 | 2 | 0 | 2 | | 2014 | 0 | 2 | 2 | | 2013 | 2 | 0 | 2 | | 2012 | 1 | 0 | 1 | | 2011 | 0 | 1 | 1 | | 2010 | 2 | 1 | 3 | | 2008 | 1 | 0 | 1 | | 2007 | 2 | 1 | 3 | | 2006 | 0 | 1 | 1 | | 2005 | 0 | 2 | 2 | | 2004 | 2 | 0 | 2 | | 2002 | 3 | 1 | 4 | | 2001 | 2 | 1 | 3 | | 2000 | 1 | 0 | 1 | | 1999 | 2 | 0 | 2 | | 1998 | 2 | 0 | 2 | | 1995 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Androgen" by people in Profiles over the past ten years.
-
Lee LS, Sim AYL, Ong CW, Yang X, Ng CCY, Liu W, Rajasegaran V, Lim AMS, Aslim EJ, Ngo NT, Khor LY, Kanesvaran R, Allen JCJ, Tay KJ, Yuen JSP, Chong TW, Ho SSH, Teh BT, Chua MLK. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2022 04; 25(4):741-748.
-
McDermott A, Kim K, Kasper S, Ho SM, Leung YK. The androgen receptor inhibits transcription of GPER1 by preventing Sp1 and Sp3 from binding to the promoters in prostate cancer cells. Oncotarget. 2022; 13:46-60.
-
Westaby D, Viscuse PV, Ravilla R, de la Maza MLDF, Hahn A, Sharp A, de Bono J, Aparicio A, Fleming MT. Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. Am Soc Clin Oncol Educ Book. 2021 Jun; 41:e190-e202.
-
Ponnusamy S, Coss CC, Thiyagarajan T, Watts K, Hwang DJ, He Y, Selth LA, McEwan IJ, Duke CB, Pagadala J, Singh G, Wake RW, Ledbetter C, Tilley WD, Moldoveanu T, Dalton JT, Miller DD, Narayanan R. Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. Cancer Res. 2017 11 15; 77(22):6282-6298.
-
Ventetuolo CE, Mitra N, Wan F, Manichaikul A, Barr RG, Johnson C, Bluemke DA, Lima JA, Tandri H, Ouyang P, Kawut SM. Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function. Eur Respir J. 2016 Feb; 47(2):553-63.
-
Ucer S, Iyer S, Bartell SM, Martin-Millan M, Han L, Kim HN, Weinstein RS, Jilka RL, O'Brien CA, Almeida M, Manolagas SC. The Effects of Androgens on Murine Cortical Bone Do Not Require AR or ERa Signaling in Osteoblasts and Osteoclasts. J Bone Miner Res. 2015 Jul; 30(7):1138-49.
-
Lam HM, Ouyang B, Chen J, Ying J, Wang J, Wu CL, Jia L, Medvedovic M, Vessella RL, Ho SM. Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer. Endocr Relat Cancer. 2014; 21(6):903-14.
-
Wei TY, Hsia JY, Chiu SC, Su LJ, Juan CC, Lee YC, Chen JM, Chou HY, Huang JY, Huang HM, Yu CT. Methylosome protein 50 promotes androgen- and estrogen-independent tumorigenesis. Cell Signal. 2014 Dec; 26(12):2940-50.
-
Manolagas SC, O'Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013 Dec; 9(12):699-712.
-
Purushottamachar P, Godbole AM, Gediya LK, Martin MS, Vasaitis TS, Kwegyir-Afful AK, Ramalingam S, Ates-Alagoz Z, Njar VC. Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem. 2013 Jun 27; 56(12):4880-98.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|